BD (Becton, Dickinson and Company) (NYSE: BDX) has announced its rapid, point-of-care, SARS-CoV-2 antigen test for use on the BD Veritor™ Plus System has been CE marked to the IVD Directive (98/79/EC) ...

FRANKLIN LAKES, N.J., July 30, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has received U.S. Food and Drug ...

Becton, Dickinson and Company BDX — also popularly known as BD — recently received CE mark for its rapid, point-of-care, SARS-CoV-2 antigen test for utilization on the BD Veritor Plus System. The new ...

Becton, Dickinson and Company BDX, popularly known as BD, received emergency use authorization (“EUA”) from the FDA for a new, rapid antigen test, which can simultaneously identify SARS-CoV-2, ...

BD (Becton, Dickinson and Company), a leading global medical technology company, announced the receipt of an order from the Dutch Ministry of Health for 9.2 million of its rapid, point-of-care, ...

New CLIA-Waived Test Delivers Digital Results to Support Timely Clinical Decision-Making FRANKLIN LAKES, N.J., July 30, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company (BDX)), a leading global ...